Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly seen — and marketed — as a way to look and feel better generally. And Novo Nordisk, the pioneer in the field, has leaned into the shift. https://www.statnews.com/2026/09/28/glp1-marketing-shift-obesity-medicine-weight-loss-drug/